We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A bipartisan group of U.S. lawmakers is pressuring Senate leadership to vote on legislation establishing a federal importation protocol, citing recent regulatory and legislative changes.
The International Federation of Red Cross and Red Crescent Societies is establishing a new alliance with the World Health Organization, the European Centre for Disease Prevention and Control, Médecins du Monde and 20 other leading European agencies and organizations to forge a more effective response to the tuberculosis (TB) epidemic in Europe.
The world's success in eradicating polio now depends on a handful of countries, including Afghanistan, India and Pakistan, according to the independent oversight body of the UN-backed effort to wipe out the sometimes fatal disease.
Some anti-retroviral drugs used to combat HIV-infected people can also give at least partial protection against malaria, according to Australian researchers addressing a conference in the United States.
Otsuka Pharmaceutical Co., Ltd. has announced its development of Physuline 30mg, which will be released for the first time in Japan on October 24 of this year.
Ambrilia Biopharma Inc, a biopharmaceutical company developing innovative therapeutics in the fields of cancer and infectious diseases, and Merck & Co., Inc., one of the world's leading pharmaceutical companies, announced that Ambrilia has entered into an exclusive licensing agreement granting Merck -- through an affiliate -- the worldwide rights to Ambrilia's HIV/AIDS protease inhibitor (PI) program.
According to a new report, pharmaceutical and biotech companies have not fully exploited the potential outsourcing represents, having only been adopted to a limited extent to date by companies.
Barr Pharmaceuticals, Inc. announced that the formal tender offer period for the offer by Barr's European subsidiary to purchase 100% of the shares of PLIVA d.d., based in Zagreb, Croatia, has officially ended.
Israel-based drugmaker Teva Pharmaceutical Industries announced that the FDA has granted tentative approval to the company's abbreviated new drug application to market its generic version of Janssen's Risperdal (risperidone) Oral Solution, 1 mg/mL.